In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

New therapies in heart failure with reduced ejection fraction: For whom and when?
Session

Event : ESC Asia 2020

Topic : Chronic Heart Failure

  • Session type : Debate Session
  • Date : 05 December 2020
  • Time : 15:40 - 16:10

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

3 presentations in this session

Sacubitril valsartan, ivabradine and omecamtic mecarbil.

Event : ESC Asia 2020

  • Session : New therapies in heart failure with reduced ejection fraction: For whom and when?
  • Speaker : M Komajda (Paris,FR)

Vericiguat and SGLT2 inhibitors.

Event : ESC Asia 2020

  • Session : New therapies in heart failure with reduced ejection fraction: For whom and when?
  • Speaker : CS Lam (Singapore,SG)

New therapies in heart failure with reduced ejection fraction: For whom and when?

Event : ESC Asia 2020

  • Session : New therapies in heart failure with reduced ejection fraction: For whom and when?

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are